Matches in SemOpenAlex for { <https://semopenalex.org/work/W2809787209> ?p ?o ?g. }
Showing items 1 to 97 of
97
with 100 items per page.
- W2809787209 abstract "Introduction Receptor tyrosine kinases (RTKs) play important roles in cellular proliferation and differentiation. In addition, RTKs reveal oncogenic potential when their kinase activities are constitutively enhanced by point mutation, amplification, or rearrangement of the corresponding genes. We are investigating ALK (Anaplastic Lymphoma Kinase) tyrosine kinase in neuroblastoma (NB) - the most frequently occurring extracranial tumour in children, where ALK activating mutations are found. In this study we performed phosphoproteomic and a gene signature profiling of ALK activity from several different neuroblastoma cells comparing treatment with the first and third generations ALK inhibitors. Material and methods Crizotinib was one of the first ALK TKIs to be described; however the response in patients with ALK positive NB was poor. In contrast, robust and sustained clinical responses we seen in ALK rearranged IMT. Lorlatinib is a third generation ALK TKI with very positive responses in NSCLC. We treated two ALK addicted (CLB-BAR, CLB-GE) and one ALK non-addicted (SK-N-AS) NB cell lines with either crizotinib or lorlatinib and performed phosphoproteomic and RNAseq profiling to identify common targets for future combinational treatment for patients. Results and discussions Profiling of ALK addicted CLB-BAR and CLB-GE cell lines led to the identification of 3345 and 2252 phosphoproteins, respectively. Phosphorylation of the ALK receptor itself was decreased in both lines upon treatment with crizotinib or lorlatinib. Parallel RNAseq profiling was performed at 24 hours. Comparison with non-treated controls revealed 19 232 differently expressed genes. In ALK addicted cells phosphoproteomic analysis revealed more than 50 proteins that were dephosphorylated upon treatment with ALK TKIs. More than 400 genes were downregulated, and more than 600 were upregulated, upon treatment with either crizotinib or lorlatinib. As an outcome we obtained a list of predicted targets for further analysis. We focused on validation of downstream signalling molecules such as: FOXO3a/4, DUSP4 and ETV3/4. Conclusion In this study we established and compared phosphoproteomic and gene signature profiles of ALK activity in NB cells employing first and third generation ALK TKIs. This analysis has unveiled a number of leads for novel combinatorial treatment strategies for NB patients as well as an increased understanding ALK dependant signalling processes." @default.
- W2809787209 created "2018-07-10" @default.
- W2809787209 creator A5002721999 @default.
- W2809787209 creator A5007977575 @default.
- W2809787209 creator A5025880133 @default.
- W2809787209 creator A5032564835 @default.
- W2809787209 creator A5041302970 @default.
- W2809787209 creator A5044229149 @default.
- W2809787209 creator A5049461836 @default.
- W2809787209 creator A5049469623 @default.
- W2809787209 creator A5074444663 @default.
- W2809787209 date "2018-06-01" @default.
- W2809787209 modified "2023-09-25" @default.
- W2809787209 title "PO-121 ALK dependant phosphoproteome and gene expression profiling of neuroblastoma cells" @default.
- W2809787209 doi "https://doi.org/10.1136/esmoopen-2018-eacr25.162" @default.
- W2809787209 hasPublicationYear "2018" @default.
- W2809787209 type Work @default.
- W2809787209 sameAs 2809787209 @default.
- W2809787209 citedByCount "0" @default.
- W2809787209 crossrefType "journal-article" @default.
- W2809787209 hasAuthorship W2809787209A5002721999 @default.
- W2809787209 hasAuthorship W2809787209A5007977575 @default.
- W2809787209 hasAuthorship W2809787209A5025880133 @default.
- W2809787209 hasAuthorship W2809787209A5032564835 @default.
- W2809787209 hasAuthorship W2809787209A5041302970 @default.
- W2809787209 hasAuthorship W2809787209A5044229149 @default.
- W2809787209 hasAuthorship W2809787209A5049461836 @default.
- W2809787209 hasAuthorship W2809787209A5049469623 @default.
- W2809787209 hasAuthorship W2809787209A5074444663 @default.
- W2809787209 hasBestOaLocation W28097872091 @default.
- W2809787209 hasConcept C101544691 @default.
- W2809787209 hasConcept C104317684 @default.
- W2809787209 hasConcept C117643217 @default.
- W2809787209 hasConcept C126322002 @default.
- W2809787209 hasConcept C150194340 @default.
- W2809787209 hasConcept C153911025 @default.
- W2809787209 hasConcept C184235292 @default.
- W2809787209 hasConcept C18431079 @default.
- W2809787209 hasConcept C2776232967 @default.
- W2809787209 hasConcept C2776256026 @default.
- W2809787209 hasConcept C2776715637 @default.
- W2809787209 hasConcept C2778347629 @default.
- W2809787209 hasConcept C2779422266 @default.
- W2809787209 hasConcept C42362537 @default.
- W2809787209 hasConcept C502942594 @default.
- W2809787209 hasConcept C54355233 @default.
- W2809787209 hasConcept C62478195 @default.
- W2809787209 hasConcept C71924100 @default.
- W2809787209 hasConcept C81885089 @default.
- W2809787209 hasConcept C86803240 @default.
- W2809787209 hasConceptScore W2809787209C101544691 @default.
- W2809787209 hasConceptScore W2809787209C104317684 @default.
- W2809787209 hasConceptScore W2809787209C117643217 @default.
- W2809787209 hasConceptScore W2809787209C126322002 @default.
- W2809787209 hasConceptScore W2809787209C150194340 @default.
- W2809787209 hasConceptScore W2809787209C153911025 @default.
- W2809787209 hasConceptScore W2809787209C184235292 @default.
- W2809787209 hasConceptScore W2809787209C18431079 @default.
- W2809787209 hasConceptScore W2809787209C2776232967 @default.
- W2809787209 hasConceptScore W2809787209C2776256026 @default.
- W2809787209 hasConceptScore W2809787209C2776715637 @default.
- W2809787209 hasConceptScore W2809787209C2778347629 @default.
- W2809787209 hasConceptScore W2809787209C2779422266 @default.
- W2809787209 hasConceptScore W2809787209C42362537 @default.
- W2809787209 hasConceptScore W2809787209C502942594 @default.
- W2809787209 hasConceptScore W2809787209C54355233 @default.
- W2809787209 hasConceptScore W2809787209C62478195 @default.
- W2809787209 hasConceptScore W2809787209C71924100 @default.
- W2809787209 hasConceptScore W2809787209C81885089 @default.
- W2809787209 hasConceptScore W2809787209C86803240 @default.
- W2809787209 hasLocation W28097872091 @default.
- W2809787209 hasOpenAccess W2809787209 @default.
- W2809787209 hasPrimaryLocation W28097872091 @default.
- W2809787209 hasRelatedWork W1601293742 @default.
- W2809787209 hasRelatedWork W1612091328 @default.
- W2809787209 hasRelatedWork W1964315027 @default.
- W2809787209 hasRelatedWork W2012311221 @default.
- W2809787209 hasRelatedWork W2021245066 @default.
- W2809787209 hasRelatedWork W2093235193 @default.
- W2809787209 hasRelatedWork W2103977904 @default.
- W2809787209 hasRelatedWork W2144615523 @default.
- W2809787209 hasRelatedWork W2316744988 @default.
- W2809787209 hasRelatedWork W2329600152 @default.
- W2809787209 hasRelatedWork W2552037618 @default.
- W2809787209 hasRelatedWork W2729139356 @default.
- W2809787209 hasRelatedWork W2884617673 @default.
- W2809787209 hasRelatedWork W2887622849 @default.
- W2809787209 hasRelatedWork W2895841271 @default.
- W2809787209 hasRelatedWork W3116177975 @default.
- W2809787209 hasRelatedWork W3135532149 @default.
- W2809787209 hasRelatedWork W3185707969 @default.
- W2809787209 hasRelatedWork W4226440628 @default.
- W2809787209 hasRelatedWork W2740521245 @default.
- W2809787209 isParatext "false" @default.
- W2809787209 isRetracted "false" @default.
- W2809787209 magId "2809787209" @default.
- W2809787209 workType "article" @default.